Article | July 1, 2022

Successfully Selecting Sites For A Psychedelic Trial

Source: Worldwide Clinical Trials
GettyImages-1354172420-lab-development

The psychedelic clinical development pipeline is growing, and competition for experienced sites has the potential to slow startup timelines. That’s because, although more sites are beginning to participate in these trials, the number of experienced sites is still limited, leading to an overall dearth of options.

As a result, sometimes it’s necessary to explore selection of sites with psychiatric trial experience – but that have not worked with psychedelics specifically. Here are a few considerations to help you select the sites with the least risk.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader